COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 2a Trial of CC-42344 Extended On December 31, 2024, Cocrystal ...

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 via allosteric targeting of the embryonic ectoderm ...

As of January 6, 2025, there were six evaluable patients in the Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX in ...

The CONNEX program consisted of the randomized, double-blind, placebo-controlled phase 3 CONNEX-1, CONNEX-2, and CONNEX-3 studies ...